David Nierengarten
Stock Analyst at Wedbush
(4.17)
# 346
Out of 5,180 analysts
222
Total ratings
52.03%
Success rate
13.01%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Maintains: Outperform | $56 → $58 | $49.16 | +17.98% | 8 | Apr 1, 2026 | |
| BCAX Bicara Therapeutics | Reiterates: Outperform | $30 | $19.89 | +50.83% | 4 | Mar 31, 2026 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $11 | $4.29 | +156.41% | 13 | Mar 27, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $4.17 | +163.79% | 6 | Mar 18, 2026 | |
| COGT Cogent Biosciences | Reiterates: Outperform | $55 | $38.49 | +42.89% | 5 | Mar 17, 2026 | |
| ARGX argenx SE | Reiterates: Outperform | $1,000 | $730.25 | +36.94% | 25 | Mar 9, 2026 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $8 | $6.43 | +24.42% | 2 | Mar 6, 2026 | |
| TCRX TScan Therapeutics | Maintains: Outperform | $4 → $5 | $1.01 | +395.05% | 5 | Mar 5, 2026 | |
| APGE Apogee Therapeutics | Maintains: Outperform | $90 → $95 | $84.17 | +12.87% | 4 | Mar 3, 2026 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $57 → $65 | $23.83 | +172.77% | 4 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $53 | $48.15 | +10.07% | 6 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $12.67 | +57.85% | 10 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $110 | $111.35 | -1.21% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $88 | $63.94 | +37.63% | 5 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $21.87 | +41.75% | 7 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $18 | $10.90 | +65.14% | 9 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $8.95 | +179.33% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $7 | $12.82 | -45.40% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $1.20 | +483.33% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $115 | $102.45 | +12.25% | 6 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $12.06 | +115.59% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $9.57 | +129.89% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $17.84 | -55.16% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $24.91 | -19.71% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $55.46 | -27.88% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $49.05 | -18.45% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $50.44 | -10.79% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $6.44 | +179.50% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.48 | +244.83% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $1.51 | +33,012.58% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $5.57 | +977.20% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $6.15 | +208.94% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $20.95 | +258.00% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.10 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.86 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.72 | - | 3 | Nov 20, 2017 |
Scholar Rock Holding
Apr 1, 2026
Maintains: Outperform
Price Target: $56 → $58
Current: $49.16
Upside: +17.98%
Bicara Therapeutics
Mar 31, 2026
Reiterates: Outperform
Price Target: $30
Current: $19.89
Upside: +50.83%
Nuvation Bio
Mar 27, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.29
Upside: +156.41%
Perspective Therapeutics
Mar 18, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.17
Upside: +163.79%
Cogent Biosciences
Mar 17, 2026
Reiterates: Outperform
Price Target: $55
Current: $38.49
Upside: +42.89%
argenx SE
Mar 9, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $730.25
Upside: +36.94%
Shattuck Labs
Mar 6, 2026
Maintains: Outperform
Price Target: $4 → $8
Current: $6.43
Upside: +24.42%
TScan Therapeutics
Mar 5, 2026
Maintains: Outperform
Price Target: $4 → $5
Current: $1.01
Upside: +395.05%
Apogee Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $90 → $95
Current: $84.17
Upside: +12.87%
Beam Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $57 → $65
Current: $23.83
Upside: +172.77%
Feb 25, 2026
Maintains: Outperform
Price Target: $50 → $53
Current: $48.15
Upside: +10.07%
Feb 24, 2026
Reiterates: Outperform
Price Target: $20
Current: $12.67
Upside: +57.85%
Feb 24, 2026
Initiates: Underperform
Price Target: $110
Current: $111.35
Upside: -1.21%
Feb 17, 2026
Maintains: Outperform
Price Target: $110 → $88
Current: $63.94
Upside: +37.63%
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $21.87
Upside: +41.75%
Jan 15, 2026
Reiterates: Neutral
Price Target: $18
Current: $10.90
Upside: +65.14%
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $8.95
Upside: +179.33%
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $12.82
Upside: -45.40%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.20
Upside: +483.33%
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $102.45
Upside: +12.25%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $12.06
Upside: +115.59%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $9.57
Upside: +129.89%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $17.84
Upside: -55.16%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $24.91
Upside: -19.71%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $55.46
Upside: -27.88%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $49.05
Upside: -18.45%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $50.44
Upside: -10.79%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $6.44
Upside: +179.50%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.48
Upside: +244.83%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $1.51
Upside: +33,012.58%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $5.57
Upside: +977.20%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $6.15
Upside: +208.94%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $20.95
Upside: +258.00%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.10
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.86
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $9.72
Upside: -